nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—ABCG2—Topotecan—cervical cancer	0.593	0.822	CbGbCtD
Vemurafenib—CYP3A4—Topotecan—cervical cancer	0.128	0.178	CbGbCtD
Vemurafenib—BRAF—endometrium—cervical cancer	0.00688	0.058	CbGeAlD
Vemurafenib—BRAF—uterus—cervical cancer	0.00634	0.0534	CbGeAlD
Vemurafenib—BRAF—female gonad—cervical cancer	0.00518	0.0437	CbGeAlD
Vemurafenib—BRAF—vagina—cervical cancer	0.00515	0.0434	CbGeAlD
Vemurafenib—RAF1—epithelium—cervical cancer	0.00511	0.0431	CbGeAlD
Vemurafenib—RAF1—uterine cervix—cervical cancer	0.00507	0.0427	CbGeAlD
Vemurafenib—RAF1—decidua—cervical cancer	0.00483	0.0407	CbGeAlD
Vemurafenib—RAF1—renal system—cervical cancer	0.00474	0.04	CbGeAlD
Vemurafenib—RAF1—endometrium—cervical cancer	0.00458	0.0386	CbGeAlD
Vemurafenib—RAF1—mammalian vulva—cervical cancer	0.00443	0.0374	CbGeAlD
Vemurafenib—RAF1—uterus—cervical cancer	0.00422	0.0356	CbGeAlD
Vemurafenib—RAF1—female reproductive system—cervical cancer	0.0038	0.032	CbGeAlD
Vemurafenib—RAF1—female gonad—cervical cancer	0.00345	0.0291	CbGeAlD
Vemurafenib—RAF1—vagina—cervical cancer	0.00343	0.0289	CbGeAlD
Vemurafenib—BRAF—lymph node—cervical cancer	0.00333	0.0281	CbGeAlD
Vemurafenib—ORM1—endometrium—cervical cancer	0.00316	0.0267	CbGeAlD
Vemurafenib—ORM1—female reproductive system—cervical cancer	0.00262	0.0221	CbGeAlD
Vemurafenib—ABCC1—uterine cervix—cervical cancer	0.00253	0.0213	CbGeAlD
Vemurafenib—ABCC1—decidua—cervical cancer	0.00241	0.0203	CbGeAlD
Vemurafenib—ABCC1—endometrium—cervical cancer	0.00229	0.0193	CbGeAlD
Vemurafenib—RAF1—lymph node—cervical cancer	0.00222	0.0187	CbGeAlD
Vemurafenib—ABCC1—mammalian vulva—cervical cancer	0.00221	0.0187	CbGeAlD
Vemurafenib—ABCC1—uterus—cervical cancer	0.00211	0.0178	CbGeAlD
Vemurafenib—ABCG2—uterine cervix—cervical cancer	0.0021	0.0177	CbGeAlD
Vemurafenib—ABCG2—decidua—cervical cancer	0.002	0.0168	CbGeAlD
Vemurafenib—Rigors—Topotecan—cervical cancer	0.00196	0.0846	CcSEcCtD
Vemurafenib—ABCG2—endometrium—cervical cancer	0.0019	0.016	CbGeAlD
Vemurafenib—CYP1A2—renal system—cervical cancer	0.00189	0.0159	CbGeAlD
Vemurafenib—ABCG2—mammalian vulva—cervical cancer	0.00183	0.0155	CbGeAlD
Vemurafenib—ABCG2—uterus—cervical cancer	0.00175	0.0147	CbGeAlD
Vemurafenib—ABCC1—female gonad—cervical cancer	0.00173	0.0146	CbGeAlD
Vemurafenib—ABCC1—vagina—cervical cancer	0.00172	0.0145	CbGeAlD
Vemurafenib—ORM1—lymph node—cervical cancer	0.00153	0.0129	CbGeAlD
Vemurafenib—Rash maculo-papular—Topotecan—cervical cancer	0.00145	0.0628	CcSEcCtD
Vemurafenib—Neoplasm—Topotecan—cervical cancer	0.00145	0.0625	CcSEcCtD
Vemurafenib—ABCG2—female gonad—cervical cancer	0.00143	0.012	CbGeAlD
Vemurafenib—ABCG2—vagina—cervical cancer	0.00142	0.012	CbGeAlD
Vemurafenib—CYP3A4—renal system—cervical cancer	0.00137	0.0115	CbGeAlD
Vemurafenib—ALB—lymph node—cervical cancer	0.00134	0.0113	CbGeAlD
Vemurafenib—CYP2D6—renal system—cervical cancer	0.00134	0.0113	CbGeAlD
Vemurafenib—ABCC1—lymph node—cervical cancer	0.00111	0.00935	CbGeAlD
Vemurafenib—CYP3A4—female reproductive system—cervical cancer	0.00109	0.00922	CbGeAlD
Vemurafenib—CYP2D6—female reproductive system—cervical cancer	0.00108	0.00908	CbGeAlD
Vemurafenib—CYP2D6—female gonad—cervical cancer	0.000979	0.00826	CbGeAlD
Vemurafenib—ABCG2—lymph node—cervical cancer	0.000918	0.00774	CbGeAlD
Vemurafenib—Infestation NOS—Topotecan—cervical cancer	0.000894	0.0387	CcSEcCtD
Vemurafenib—Infestation—Topotecan—cervical cancer	0.000894	0.0387	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Topotecan—cervical cancer	0.000876	0.0379	CcSEcCtD
Vemurafenib—Angiopathy—Topotecan—cervical cancer	0.000728	0.0315	CcSEcCtD
Vemurafenib—Mediastinal disorder—Topotecan—cervical cancer	0.000723	0.0313	CcSEcCtD
Vemurafenib—Chills—Topotecan—cervical cancer	0.00072	0.0311	CcSEcCtD
Vemurafenib—Alopecia—Topotecan—cervical cancer	0.000709	0.0307	CcSEcCtD
Vemurafenib—Malnutrition—Topotecan—cervical cancer	0.000699	0.0302	CcSEcCtD
Vemurafenib—Back pain—Topotecan—cervical cancer	0.000676	0.0292	CcSEcCtD
Vemurafenib—Cough—Topotecan—cervical cancer	0.00061	0.0264	CcSEcCtD
Vemurafenib—Myalgia—Topotecan—cervical cancer	0.000595	0.0257	CcSEcCtD
Vemurafenib—Arthralgia—Topotecan—cervical cancer	0.000595	0.0257	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.000591	0.0255	CcSEcCtD
Vemurafenib—Anaphylactic shock—Topotecan—cervical cancer	0.00057	0.0247	CcSEcCtD
Vemurafenib—Infection—Topotecan—cervical cancer	0.000566	0.0245	CcSEcCtD
Vemurafenib—Nervous system disorder—Topotecan—cervical cancer	0.000559	0.0242	CcSEcCtD
Vemurafenib—Skin disorder—Topotecan—cervical cancer	0.000554	0.0239	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00052	0.0225	CcSEcCtD
Vemurafenib—Decreased appetite—Topotecan—cervical cancer	0.000496	0.0214	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Topotecan—cervical cancer	0.000492	0.0213	CcSEcCtD
Vemurafenib—Fatigue—Topotecan—cervical cancer	0.000492	0.0213	CcSEcCtD
Vemurafenib—Constipation—Topotecan—cervical cancer	0.000488	0.0211	CcSEcCtD
Vemurafenib—Body temperature increased—Topotecan—cervical cancer	0.000451	0.0195	CcSEcCtD
Vemurafenib—Hypersensitivity—Topotecan—cervical cancer	0.00042	0.0182	CcSEcCtD
Vemurafenib—Asthenia—Topotecan—cervical cancer	0.000409	0.0177	CcSEcCtD
Vemurafenib—Pruritus—Topotecan—cervical cancer	0.000403	0.0174	CcSEcCtD
Vemurafenib—Diarrhoea—Topotecan—cervical cancer	0.00039	0.0169	CcSEcCtD
Vemurafenib—Dizziness—Topotecan—cervical cancer	0.000377	0.0163	CcSEcCtD
Vemurafenib—Vomiting—Topotecan—cervical cancer	0.000363	0.0157	CcSEcCtD
Vemurafenib—Rash—Topotecan—cervical cancer	0.00036	0.0155	CcSEcCtD
Vemurafenib—Dermatitis—Topotecan—cervical cancer	0.000359	0.0155	CcSEcCtD
Vemurafenib—Headache—Topotecan—cervical cancer	0.000357	0.0154	CcSEcCtD
Vemurafenib—Nausea—Topotecan—cervical cancer	0.000339	0.0146	CcSEcCtD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—FGFR3—cervical cancer	0.00032	0.00234	CbGpPWpGaD
Vemurafenib—RAF1—Regulation of Actin Cytoskeleton—FGFR3—cervical cancer	0.00032	0.00234	CbGpPWpGaD
Vemurafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—CTNNB1—cervical cancer	0.000316	0.00231	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—FGFR3—cervical cancer	0.000315	0.00231	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—GP5—cervical cancer	0.000312	0.00229	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways in Glioblastoma—TP53—cervical cancer	0.00031	0.00227	CbGpPWpGaD
Vemurafenib—RAF1—Corticotropin-releasing hormone—CASP3—cervical cancer	0.000305	0.00223	CbGpPWpGaD
Vemurafenib—RAF1—TNF alpha Signaling Pathway—CASP3—cervical cancer	0.000305	0.00223	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR—MTOR—cervical cancer	0.000305	0.00223	CbGpPWpGaD
Vemurafenib—BRAF—EGF/EGFR Signaling Pathway—MTOR—cervical cancer	0.000305	0.00223	CbGpPWpGaD
Vemurafenib—RAF1—AGE/RAGE pathway—EGFR—cervical cancer	0.000304	0.00222	CbGpPWpGaD
Vemurafenib—BRAF—ErbB1 downstream signaling—EGFR—cervical cancer	0.000303	0.00221	CbGpPWpGaD
Vemurafenib—RAF1—Leptin signaling pathway—STAT3—cervical cancer	0.000302	0.00221	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—FGFR3—cervical cancer	0.000301	0.0022	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—FGFR3—cervical cancer	0.0003	0.00219	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—MTOR—cervical cancer	0.000298	0.00218	CbGpPWpGaD
Vemurafenib—RAF1—ErbB1 downstream signaling—MTOR—cervical cancer	0.000298	0.00218	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—FGFR3—cervical cancer	0.000298	0.00218	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—FGFR3—cervical cancer	0.000297	0.00217	CbGpPWpGaD
Vemurafenib—BRAF—Integrated Breast Cancer Pathway—CASP3—cervical cancer	0.000296	0.00217	CbGpPWpGaD
Vemurafenib—RAF1—Corticotropin-releasing hormone—CTNNB1—cervical cancer	0.000294	0.00215	CbGpPWpGaD
Vemurafenib—RAF1—VEGFA-VEGFR2 Pathway—MTOR—cervical cancer	0.000294	0.00215	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—UBE3A—cervical cancer	0.000292	0.00214	CbGpPWpGaD
Vemurafenib—BRAF—PDGFR-beta signaling pathway—STAT3—cervical cancer	0.00029	0.00212	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—MTHFR—cervical cancer	0.000287	0.0021	CbGpPWpGaD
Vemurafenib—BRAF—Integrated Breast Cancer Pathway—CTNNB1—cervical cancer	0.000286	0.00209	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR in disease—MTOR—cervical cancer	0.000284	0.00208	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—FGFR3—cervical cancer	0.000279	0.00204	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—FGFR3—cervical cancer	0.000279	0.00204	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—FGFR3—cervical cancer	0.000279	0.00204	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by VEGF—MTOR—cervical cancer	0.000277	0.00203	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—FGFR3—cervical cancer	0.000277	0.00202	CbGpPWpGaD
Vemurafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—STAT3—cervical cancer	0.000275	0.00202	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Insulin receptor—MTOR—cervical cancer	0.000275	0.00201	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—FGFR3—cervical cancer	0.000275	0.00201	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—FGFR3—cervical cancer	0.000274	0.00201	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—FGFR3—cervical cancer	0.000273	0.002	CbGpPWpGaD
Vemurafenib—BRAF—MAPK Signaling Pathway—CASP3—cervical cancer	0.000272	0.00199	CbGpPWpGaD
Vemurafenib—RAF1—VEGFA-VEGFR2 Pathway—CTNNB1—cervical cancer	0.00026	0.00191	CbGpPWpGaD
Vemurafenib—RAF1—Oncostatin M Signaling Pathway—TP53—cervical cancer	0.000258	0.00189	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways in Glioblastoma—EGFR—cervical cancer	0.000255	0.00187	CbGpPWpGaD
Vemurafenib—BRAF—Senescence and Autophagy in Cancer—TP53—cervical cancer	0.000254	0.00186	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—HLA-DQB1—cervical cancer	0.000253	0.00185	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—TAAR6—cervical cancer	0.000252	0.00185	CbGpPWpGaD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—MTOR—cervical cancer	0.000251	0.00184	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—CASP8—cervical cancer	0.000249	0.00182	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—FGFR3—cervical cancer	0.000247	0.00181	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by VEGF—CTNNB1—cervical cancer	0.000246	0.0018	CbGpPWpGaD
Vemurafenib—BRAF—Disease—WNT2—cervical cancer	0.00024	0.00176	CbGpPWpGaD
Vemurafenib—BRAF—Focal Adhesion—CTNNB1—cervical cancer	0.000238	0.00174	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—MTOR—cervical cancer	0.000236	0.00172	CbGpPWpGaD
Vemurafenib—BRAF—EGF/EGFR Signaling Pathway—STAT3—cervical cancer	0.000235	0.00172	CbGpPWpGaD
Vemurafenib—RAF1—BDNF signaling pathway—MTOR—cervical cancer	0.000232	0.00169	CbGpPWpGaD
Vemurafenib—RAF1—ErbB1 downstream signaling—STAT3—cervical cancer	0.00023	0.00169	CbGpPWpGaD
Vemurafenib—BRAF—Regulation of Actin Cytoskeleton—EGFR—cervical cancer	0.000229	0.00167	CbGpPWpGaD
Vemurafenib—BRAF—Integrated Breast Cancer Pathway—EGFR—cervical cancer	0.000226	0.00166	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—MTOR—cervical cancer	0.000225	0.00165	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Interleukins—STAT3—cervical cancer	0.000225	0.00165	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	0.000225	0.00164	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—MTOR—cervical cancer	0.000222	0.00162	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR in disease—STAT3—cervical cancer	0.000219	0.0016	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TAAR6—cervical cancer	0.000216	0.00158	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways in Glioblastoma—TP53—cervical cancer	0.000214	0.00157	CbGpPWpGaD
Vemurafenib—BRAF—EGF/EGFR Signaling Pathway—EGFR—cervical cancer	0.000214	0.00157	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR—EGFR—cervical cancer	0.000214	0.00157	CbGpPWpGaD
Vemurafenib—RAF1—BDNF signaling pathway—CASP3—cervical cancer	0.000213	0.00156	CbGpPWpGaD
Vemurafenib—RAF1—Insulin Signaling—MTOR—cervical cancer	0.000213	0.00156	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—MTOR—cervical cancer	0.000212	0.00155	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—MTOR—cervical cancer	0.000211	0.00154	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—MTOR—cervical cancer	0.000211	0.00154	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—MTOR—cervical cancer	0.00021	0.00153	CbGpPWpGaD
Vemurafenib—RAF1—ErbB1 downstream signaling—EGFR—cervical cancer	0.000209	0.00153	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—MTOR—cervical cancer	0.000209	0.00153	CbGpPWpGaD
Vemurafenib—BRAF—MAPK Signaling Pathway—EGFR—cervical cancer	0.000208	0.00152	CbGpPWpGaD
Vemurafenib—RAF1—BDNF signaling pathway—CTNNB1—cervical cancer	0.000205	0.0015	CbGpPWpGaD
Vemurafenib—RAF1—Retinoblastoma (RB) in Cancer—TP53—cervical cancer	0.000204	0.0015	CbGpPWpGaD
Vemurafenib—RAF1—PDGFR-beta signaling pathway—STAT3—cervical cancer	0.0002	0.00147	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR in disease—EGFR—cervical cancer	0.000199	0.00146	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—WNT2—cervical cancer	0.000197	0.00144	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—MTOR—cervical cancer	0.000196	0.00144	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—MTOR—cervical cancer	0.000196	0.00144	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—MTOR—cervical cancer	0.000196	0.00144	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—MTOR—cervical cancer	0.000195	0.00142	CbGpPWpGaD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—STAT3—cervical cancer	0.000194	0.00142	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—MTOR—cervical cancer	0.000193	0.00141	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—MTOR—cervical cancer	0.000193	0.00141	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—MTOR—cervical cancer	0.000192	0.0014	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—FGFR3—cervical cancer	0.00019	0.00139	CbGpPWpGaD
Vemurafenib—BRAF—Integrated Breast Cancer Pathway—TP53—cervical cancer	0.00019	0.00139	CbGpPWpGaD
Vemurafenib—BRAF—Focal Adhesion—EGFR—cervical cancer	0.000188	0.00138	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—CASP3—cervical cancer	0.000188	0.00138	CbGpPWpGaD
Vemurafenib—BRAF—Disease—WNT5A—cervical cancer	0.000182	0.00133	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—STAT3—cervical cancer	0.000182	0.00133	CbGpPWpGaD
Vemurafenib—RAF1—BDNF signaling pathway—STAT3—cervical cancer	0.000179	0.00131	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—CASP3—cervical cancer	0.000178	0.0013	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—UBE3A—cervical cancer	0.000177	0.0013	CbGpPWpGaD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—EGFR—cervical cancer	0.000177	0.00129	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—TP53—cervical cancer	0.000176	0.00129	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HLA-DPB1—cervical cancer	0.000175	0.00128	CbGpPWpGaD
Vemurafenib—BRAF—MAPK Signaling Pathway—TP53—cervical cancer	0.000174	0.00128	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—MTOR—cervical cancer	0.000174	0.00127	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AKAP13—cervical cancer	0.000173	0.00127	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	0.00017	0.00124	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—WNT2—cervical cancer	0.000168	0.00123	CbGpPWpGaD
Vemurafenib—RAF1—Disease—WNT2—cervical cancer	0.000166	0.00122	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—EGFR—cervical cancer	0.000165	0.00121	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—WNT2—cervical cancer	0.000165	0.00121	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—CTNNB1—cervical cancer	0.000164	0.0012	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	0.000164	0.0012	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—STAT3—cervical cancer	0.000164	0.0012	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—STAT3—cervical cancer	0.000163	0.00119	CbGpPWpGaD
Vemurafenib—RAF1—Regulation of Actin Cytoskeleton—EGFR—cervical cancer	0.000158	0.00116	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—EGFR—cervical cancer	0.000158	0.00116	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—EGFR—cervical cancer	0.000156	0.00114	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—HES1—cervical cancer	0.000153	0.00112	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—cervical cancer	0.000153	0.00112	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—cervical cancer	0.000153	0.00112	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—STAT3—cervical cancer	0.000152	0.00111	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—STAT3—cervical cancer	0.000149	0.00109	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—WNT5A—cervical cancer	0.000149	0.00109	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TAAR6—cervical cancer	0.000149	0.00109	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—EGFR—cervical cancer	0.000149	0.00109	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—STAT3—cervical cancer	0.000148	0.00109	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—EGFR—cervical cancer	0.000148	0.00108	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—EGFR—cervical cancer	0.000148	0.00108	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AKAP13—cervical cancer	0.000148	0.00108	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—EGFR—cervical cancer	0.000147	0.00108	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—EGFR—cervical cancer	0.000147	0.00107	CbGpPWpGaD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—TP53—cervical cancer	0.000146	0.00107	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—EGFR—cervical cancer	0.000144	0.00105	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—EGFR—cervical cancer	0.000138	0.00101	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—EGFR—cervical cancer	0.000138	0.00101	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—EGFR—cervical cancer	0.000138	0.00101	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—TP53—cervical cancer	0.000137	0.001	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—EGFR—cervical cancer	0.000137	0.001	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HLA-DQB1—cervical cancer	0.000136	0.000997	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—EGFR—cervical cancer	0.000136	0.000993	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—EGFR—cervical cancer	0.000135	0.000991	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—EGFR—cervical cancer	0.000135	0.000987	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—STAT3—cervical cancer	0.000134	0.000983	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—MTOR—cervical cancer	0.000134	0.000979	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CA9—cervical cancer	0.00013	0.000954	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—EGFR—cervical cancer	0.00013	0.000953	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	0.00013	0.000949	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—WNT5A—cervical cancer	0.000128	0.000933	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD8A—cervical cancer	0.000127	0.000931	CbGpPWpGaD
Vemurafenib—RAF1—Disease—WNT5A—cervical cancer	0.000126	0.000922	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—WNT5A—cervical cancer	0.000125	0.000914	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—CASP3—cervical cancer	0.000123	0.0009	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—EGFR—cervical cancer	0.000122	0.000894	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TP53—cervical cancer	0.000121	0.000883	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	0.000118	0.000864	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—WNT2—cervical cancer	0.000116	0.000852	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—NOTCH1—cervical cancer	0.000115	0.000843	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CA9—cervical cancer	0.000115	0.000839	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	0.000109	0.000797	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—FGFR3—cervical cancer	0.000108	0.000793	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-DPB1—cervical cancer	0.000106	0.000775	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—STAT3—cervical cancer	0.000105	0.000769	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HES1—cervical cancer	0.000105	0.000767	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—FGFR3—cervical cancer	0.000104	0.000762	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—STAT3—cervical cancer	0.000103	0.000756	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKAP13—cervical cancer	0.000102	0.000748	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—EGFR—cervical cancer	9.39e-05	0.000687	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CASP8—cervical cancer	9.27e-05	0.000678	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MTHFR—cervical cancer	9.21e-05	0.000674	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TERT—cervical cancer	9.18e-05	0.000672	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NOTCH2—cervical cancer	8.95e-05	0.000655	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—WNT5A—cervical cancer	8.82e-05	0.000646	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—EGFR—cervical cancer	8.5e-05	0.000622	CbGpPWpGaD
Vemurafenib—BRAF—Disease—FGFR3—cervical cancer	8.43e-05	0.000617	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-DQB1—cervical cancer	8.27e-05	0.000605	CbGpPWpGaD
Vemurafenib—BRAF—Disease—NOTCH1—cervical cancer	7.91e-05	0.000579	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD8A—cervical cancer	7.72e-05	0.000565	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—CTNNB1—cervical cancer	7.66e-05	0.00056	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—MTOR—cervical cancer	7.63e-05	0.000558	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CD4—cervical cancer	7.61e-05	0.000557	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HES1—cervical cancer	7.34e-05	0.000537	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—MTOR—cervical cancer	7.33e-05	0.000536	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD4—cervical cancer	7.31e-05	0.000535	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HES1—cervical cancer	7.25e-05	0.000531	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HES1—cervical cancer	7.19e-05	0.000526	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CA9—cervical cancer	7.08e-05	0.000518	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CTNNB1—cervical cancer	6.76e-05	0.000495	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—STAT3—cervical cancer	6.68e-05	0.000488	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TERT—cervical cancer	6.43e-05	0.000471	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MTHFR—cervical cancer	6.37e-05	0.000466	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TERT—cervical cancer	6.35e-05	0.000465	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MTHFR—cervical cancer	6.32e-05	0.000462	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—FGFR3—cervical cancer	6.32e-05	0.000462	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TERT—cervical cancer	6.3e-05	0.000461	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NOTCH2—cervical cancer	6.19e-05	0.000453	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—EGFR—cervical cancer	6.07e-05	0.000444	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MTOR—cervical cancer	5.93e-05	0.000434	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CD4—cervical cancer	5.92e-05	0.000433	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—FGFR3—cervical cancer	5.9e-05	0.000432	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CA9—cervical cancer	5.84e-05	0.000428	CbGpPWpGaD
Vemurafenib—RAF1—Disease—FGFR3—cervical cancer	5.83e-05	0.000427	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—FGFR3—cervical cancer	5.78e-05	0.000423	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NOTCH1—cervical cancer	5.54e-05	0.000405	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NOTCH1—cervical cancer	5.47e-05	0.000401	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NOTCH1—cervical cancer	5.43e-05	0.000397	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CASP8—cervical cancer	5.4e-05	0.000395	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—EGFR—cervical cancer	5.36e-05	0.000392	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—MTHFR—cervical cancer	5.29e-05	0.000387	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CTNNB1—cervical cancer	5.26e-05	0.000385	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—EGFR—cervical cancer	5.15e-05	0.000376	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HES1—cervical cancer	5.08e-05	0.000372	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—cervical cancer	5e-05	0.000366	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CA9—cervical cancer	4.95e-05	0.000362	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—MTHFR—cervical cancer	4.65e-05	0.000341	CbGpPWpGaD
Vemurafenib—BRAF—Disease—STAT3—cervical cancer	4.58e-05	0.000335	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TERT—cervical cancer	4.45e-05	0.000326	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MTOR—cervical cancer	4.44e-05	0.000325	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD4—cervical cancer	4.43e-05	0.000324	CbGpPWpGaD
Vemurafenib—BRAF—Disease—EGFR—cervical cancer	4.16e-05	0.000305	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MTOR—cervical cancer	4.15e-05	0.000304	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MTOR—cervical cancer	4.1e-05	0.0003	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CD4—cervical cancer	4.09e-05	0.0003	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FGFR3—cervical cancer	4.08e-05	0.000299	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MTOR—cervical cancer	4.07e-05	0.000298	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CD4—cervical cancer	4.06e-05	0.000297	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CTNNB1—cervical cancer	3.94e-05	0.000288	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NOTCH1—cervical cancer	3.83e-05	0.00028	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CA9—cervical cancer	3.82e-05	0.00028	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CASP3—cervical cancer	3.82e-05	0.000279	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CTNNB1—cervical cancer	3.68e-05	0.000269	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CTNNB1—cervical cancer	3.64e-05	0.000266	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CTNNB1—cervical cancer	3.61e-05	0.000264	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—STAT3—cervical cancer	3.43e-05	0.000251	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EGFR—cervical cancer	3.42e-05	0.00025	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—STAT3—cervical cancer	3.21e-05	0.000235	CbGpPWpGaD
Vemurafenib—RAF1—Disease—STAT3—cervical cancer	3.17e-05	0.000232	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—STAT3—cervical cancer	3.14e-05	0.00023	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EGFR—cervical cancer	3.12e-05	0.000228	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EGFR—cervical cancer	2.92e-05	0.000213	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EGFR—cervical cancer	2.88e-05	0.000211	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MTOR—cervical cancer	2.87e-05	0.00021	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MTHFR—cervical cancer	2.87e-05	0.00021	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EGFR—cervical cancer	2.86e-05	0.000209	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—cervical cancer	2.69e-05	0.000197	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CASP3—cervical cancer	2.64e-05	0.000193	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CTNNB1—cervical cancer	2.55e-05	0.000186	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—cervical cancer	2.45e-05	0.000179	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MTHFR—cervical cancer	2.37e-05	0.000174	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—STAT3—cervical cancer	2.22e-05	0.000162	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGFR—cervical cancer	2.02e-05	0.000148	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MTHFR—cervical cancer	2.01e-05	0.000147	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—cervical cancer	1.69e-05	0.000124	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MTHFR—cervical cancer	1.55e-05	0.000113	CbGpPWpGaD
